Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.
Md Yuzaiful Md YusofEdward M VitalDamien M McElvennyElizabeth M A HensorSudipto DasShouvik DassAndy C RawstronMaya H BuchPaul EmerySinisa SavicPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2019)
Immunoglobulin levels should be monitored at baseline and before each RTX cycle to identify patients at risk of SIEs. Individualized risk-benefit assessment should be undertaken in those with lower IgG as this is a consistent SIE predictor and may increase infection profiles when RTX is switched to different therapies.